Plasma derived from human umbilical cord blood: Potential cell‐additive or cell‐substitute therapeutic for neurodegenerative diseases

Abstract

Limited efficacy of current therapeutic approaches for neurodegenerative disease has led to increased interest in alternative therapies. Cord blood plasma (CBP) derived from human umbilical cord blood (hUCB) may be a potential therapeutic. Benefits of CBP injection into rodent models of aging or ischaemic stroke have been demonstrated, though how benefits are elicited is still unclear. The present study evaluated various factors within the same samples of CBP and human adult blood plasma/sera (ABP/S). Also, autologous CBP effects vs. ABP/S or foetal bovine serum supplements on mononuclear cells from hUCB (MNC hUCB) in vitro were determined. Results showed significantly low concentrations of pro‐inflammatory cytokines (IL‐2, IL‐6, IFN‐γ, and TNF‐α) and elevated chemokine IL‐8 in CBP. Significantly higher levels of VEGF, G‐CSF, EGF and FGF‐basic growth factors were determined in CBP vs. ABP/S. Autologous CBP media supplements significantly increased MNC hUCB viability and decreased apoptotic cell activity. We are first to demonstrate the unique CBP composition of cytokines and growth factors within the same CBP samples derived from hUCB. Also, our novel finding that autologous CBP promoted MNC hUCB viability and reduced apoptotic cell death in vitro supports CBP's potential as a sole therapeutic or cell‐additive agent in developing therapies for various neurodegenerative diseases.

A Gutsy Move for Cell-Based Regenerative Medicine in Parkinson’s Disease: Targeting the Gut Microbiome to Sequester Inflammation and Neurotoxicity

“…In vitro cultures of human dental cells, hUCB-derived mesenchymal stem cells (MSCs), hUCB-derived T-lymphocytes, and human endothelial colony forming cells display improved cell viability from supplementation with cord blood plasma (CBP) [38–41]. CBP is composed of a distinctive cytokine profile with low concetrations of several pro-inflammatory cytokines, as well as high amounts of growth factors [29, 38, 42, 43]. The view that CBP may confer equally potent therapeutic effects as hUCB is bolstered by the observations that anti-inflammation and neuroprotection afforded by hUCB cell transplantation [32, 44–47] is achieved by CBP infusion in experimental stroke model [43, 48].…”

“…CBP is composed of a distinctive cytokine profile with low concetrations of several pro-inflammatory cytokines, as well as high amounts of growth factors [29, 38, 42, 43]. The view that CBP may confer equally potent therapeutic effects as hUCB is bolstered by the observations that anti-inflammation and neuroprotection afforded by hUCB cell transplantation [32, 44–47] is achieved by CBP infusion in experimental stroke model [43, 48]. Our recent study shows that intravenous hUCB-derived plasma administration into the 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine (MPTP)-induced rat PD model ameliorates motor function and improves survival of dopaminergic neurons while reducing pro-inflammatory cytokines in the substantia nigra pars compacta (SNpc) [49].…”

Strategies for managing Asherman's syndrome and endometrial atrophy: Since the classical experimental models to the new bioengineering approach

“…These results suggest that the umbilical cord could be a good source of plasma for treating endometrial pathologies and other regenerative medicine applications, as demonstrated by other groups (Castellano et al, 2017;Ehrhart et al, 2018). PRP has also been tested in women with either thin endometrium (Chang et al, 2019;Eftekhar et al, 2018;Kim, Shin et al, 2019;Molina et al, 2018;Nazari et al, 2016;Tandulwadkar et al, 2017) or AS (Javaheri et al, 2020;Zadehmodarres et al, 2017).…”

The potential of cord blood to replenish young immune cells against cancer

“…Therefore, UCB is used as a cellular source for replenishing young immune cells to treat senile diseases. [6][7][8][9][10] In this article, we describe immune aging and the application of cord blood for rejuvenating aging immune cells against neoplastic diseases.…”